This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, J. Articles by Chinnaiyan, A. M. Search for Related Content PubMed PubMed Citation Articles by Yu, J. Articles by Chinnaiyan, A. M.

A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome

¹ Michigan Center for Translational Pathology, Department of Pathology, ² Department of Urology, ³ Department of Biostatistics, ⁴ Comprehensive Cancer Center, ⁵ Department of Surgery, ⁶ Bioinformatics Program, and ⁷ Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan

Requests for reprints: Arul M. Chinnaiyan, Comprehensive Cancer Center, 1400 East Medical Center Drive, Ann Arbor, MI 48109. Phone: 734-763-5824; Fax: 734-615-4498; E-mail: arul{at}umich.edu.

The Polycomb Group (PcG) protein EZH2 is a critical component of a multiprotein complex that methylates Lys²⁷ of histone 3 (H3K27), which consequently leads to the repression of target gene expression. We have previously reported that EZH2 is overexpressed in metastatic prostate cancer and is a marker of aggressive diseases in clinically localized solid tumors. However, the global set of genes directly regulated by PcG in tumors is largely unknown, and thus how PcG mediates tumor progression remains unclear. Herein we mapped genome-wide H3K27 methylation in aggressive, disseminated human prostate cancer tissues. Integrative analysis revealed that a significant subset of these genes are also targets of PcG in embryonic stem cells, and their repression in tumors is associated with poor prognosis. By stepwise cross-validation, we developed a "Polycomb repression signature" composed of 14 direct targets of PcG in metastatic tumors. Notably, solid tumor subtypes in which this gene signature is repressed show poor clinical outcome in multiple microarray data sets of tumors including breast and prostate cancer. Taken together, our results show a fingerprint of PcG-mediated transcriptional repression in metastatic prostate cancer that is reminiscent of stem cells and associated with cancer progression. Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival. [Cancer Res 2007;67(22):10657–63]

This article has been cited by other articles:

				M. T. McCabe, J. C. Brandes, and P. M. Vertino Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3927 - 3937. [Abstract] [Full Text] [PDF]

				J. M. Friedman, G. Liang, C.-C. Liu, E. M. Wolff, Y. C. Tsai, W. Ye, X. Zhou, and P. A. Jones The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2 Cancer Res., March 15, 2009; 69(6): 2623 - 2629. [Abstract] [Full Text] [PDF]

				P. Joshi, E. A. Carrington, L. Wang, C. S. Ketel, E. L. Miller, R. S. Jones, and J. A. Simon Dominant Alleles Identify SET Domain Residues Required for Histone Methyltransferase of Polycomb Repressive Complex 2 J. Biol. Chem., October 10, 2008; 283(41): 27757 - 27766. [Abstract] [Full Text] [PDF]

				B. Zhao, X. Ye, J. Yu, L. Li, W. Li, S. Li, J. Yu, J. D. Lin, C.-Y. Wang, A. M. Chinnaiyan, et al. TEAD mediates YAP-dependent gene induction and growth control Genes & Dev., July 15, 2008; 22(14): 1962 - 1971. [Abstract] [Full Text] [PDF]